The effect of excipients on the stability of levothyroxine sodium pentahydrate tablets

International Journal of Pharmaceutics

Volumn 264, Issue 1-2, 2003, Pages 35-43

  Patel, Himanshu ^a   Stalcup, Apryll ^a   Dansereau, Richard ^a   Sakr, Adel ^a  

^a UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Excipient; Levothyroxine sodium; pH modifiers; Slurries; Stability; Tablets

Indexed keywords

'ATLAS'; ACID ANHYDRIDE; AEROSIL; BICARBONATE; CALCIUM PHOSPHATE DIBASIC; CARBOHYDRATE DERIVATIVE; CROSCARMELLOSE SODIUM; CROSPOVIDONE; EXCIPIENT; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; LEVOTHYROXINE SODIUM; MAGNESIUM OXIDE; MAGNESIUM STEARATE; MANNITOL; METHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; POVIDONE; SODIUM CARBONATE; STARCH; STARCH GLYCOLATE SODIUM; STEARIC ACID;

AQUEOUS SOLUTION; ARTICLE; DRUG MANUFACTURE; DRUG STABILITY; DRUG STORAGE; PH; PRIORITY JOURNAL; SOLID STATE; STORAGE TEMPERATURE; TABLET FORMULATION; WETTABILITY;

EID: 0142028204     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(03)00387-9     Document Type: Article

References (15)

1. Andre A., Domanig R., Riemer E., Moser H., Groeppelin A. Identification and thermal degradation products of L-triiodothyroxine sodium (liothyroxine sodium) by reversed phase HPLC with photodiode-array UV and mass spectrometric detection. J. Chromatogr. A. 725:1996;287-294.
2. Badaway S.I., Williams R.C., Gilbert D.L. Effect of different acids on solid-state stability of an ester prodrug of a glycoprotein IIb/IIIa receptor antagonist. Pharm. Dev. Technol. 3:1999;4325-4331.
3. FDA Guidance for Industry (Draft), 1998. Drug Stability Testing of Drug Substance and Drug Products.
4. FDA Guidance for Industry, 2001. Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date Submission of New Application.
5. Federal Register, Thursday, 14 August, 1997, 62, 43535-43538.
6. Garnick R., Burt G., Long D., Bastian W., Aldred J. High-performance liquid chromatography assay for sodium levothyroxine in tablet formulations: content uniformity applications. J. Pharm. Sci. 73:1984;75-77.
7. Goodman, L., Gilman, A., 2001. In: Gilman, A., Hardman, J., Limbird, L. (Eds.), The Pharmacological Basis of Therapeutics, 10th ed. McGraw-Hill, New York.
8. Gupta V., Odom C., Bethea C., Plattenburg J. Effects of excipients on the stability of levothyroxine sodium tablets. J. Clin. Pharm. Ther. 15:1990;331-336.
9. ICH Steering Committee, ICH Harmonized Tripartite Guideline, Q1A(R), 2000. Stability Testing of New Drug Substances and Products.
10. Jin J., Stalcup A., Hyun M. The impact of triethylamine as a mobile phase additive on the resolution of racemic amino acids on an (+)-18-crown-6-tetracarboxylic acid-derived chiral stationary phase. J. Chromatogr. A. 933:2001;83-90.
11. Kazemifard A., Moore D., Aghazadeh A. Identification and quantitation of sodium-thyroxine and its degradation products by LC using electrochemical and MS detection. J. Pharm. Biomed. Anal. 25:2001;697-711.
12. Post, A., Warren, R., 1976. Sodium levothyroxine. In: Florey, K. (Ed.), Analytical Profiles of Drug Substances, vol. 5. Academic Press, New York, pp. 226-281.
13. Rhodes C. Regulatory aspects of the formulation and evaluation of levothyroxine tablets. Clin. Res. Reg. Aff. 15:1998;173-186.
14. Won C. Kinetics of degradation of levothyroxine in aqueous solution and in solid state. Pharm. Res. 9:1992;131-139.
15. Wortsman J., Papadimitriou D., Broges M., Defesche C. Thermal inactivation of L-thyroxin. Clin. Chem. 35:1989;90-92.